ODYY News and Press, Odyssey Group International Inc From 11/14/22

Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder The application follows the successful comple...

Chronic heart failure is known to develop over time, with experts finding that the primary causes of heart failure include coronary artery disease, myocardial infarction and high blood pressure. Now, new research has found that iron promotes fatty tissue formation within the heart, causing...

Odyssey Health is a medical company specializing in the development of unique, life-saving medical products that provide solutions to unmet clinical needs, one of which is concussion, which currently does not have an FDA-approved drug The company has developed the PRV-002 drug candidate...

Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products a...

Since the early 2000s, research on concussions has improved significantly. Concussions are traumatic brain injuries that affect the brain function of an individual. It is estimated that millions of Americans experience concussions annually, with a survey conducted by the CDC in 2017 findin...

Odyssey Health (OTC: ODYY) , formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, is expanding its executive team. The expansion is part of ODYY’s support of and commitment to Odyssey NeuroPharma, the compan...

Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, is pleased to announce its continued commitme...

Odyssey Health (OTC: ODYY) has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As previously announced, Odyssey’s recently completed phase I study to treat concussion successful...

Las Vegas, Nevada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), announces that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delive...

Odyssey Health (OTC: ODYY) recently announced the completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial. “Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to...